Patient-reported outcomes from LUCENT-1 (A) and LUCENT-2 (B) for patients with induction baseline mMS of 5–9. Error bars on the figure represent the upper limit of the 95% confidence intervals (left) and standard error (center and right). *P < .05, **P < .01, ***P < .001. IBDQ remission, IBDQ response, and systematic remission were analyzed with a Cochran-Mantel-Haenszel test with adjustment for stratification factors (corticosteroid use [yes/no] at LUCENT-1 baseline, prior biologic or tofacitinib failure [yes/no], baseline disease activity [mMS: 5–6, 7–9], and geographic region [North America, Europe, and Other]). For LUCENT-2, clinical remission at LUCENT-1 week 12 (yes/no) replaces baseline disease activity. WPAI and fatigue outcomes were analyzed with an analysis of covariance model that included trial group, baseline value, corticosteroid use (yes/no) at LUCENT-1 baseline, prior biologic or tofacitinib failure (yes/no), baseline disease activity (mMS: [5–6] or [7–9]), and geographic region (North America, Europe, and Other). For LUCENT-2, clinical remission at LUCENT-1 week 12 (yes/no) replaces baseline disease activity. Presenteeism, absenteeism, and work impairment are in patients with baseline employment. Overall work impairment score, aggregate of absenteeism and presenteeism. IBDQ, Inflammatory Bowel Disease Questionnaire; LSM, least square means; mMS, modified Mayo score; NRS, numeric rating scale; Presenteeism, reduced productivity while at work; WPAI-UC, Work Productivity and Activity Impairment Questionnaire Ulcerative Colitis